3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs
Eli Lilly has been investing in radiopharmaceuticals, which can help revolutionize cancer care in the future. Its early…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
New method could improve manufacturing of gene-therapy drugs | MIT News
Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their…
Sarepta to seek approval for gene therapy in rare muscular dystrophy
An experimental gene therapy from Sarepta Therapeutics increased levels of the gene missing in an ultra-rare form of…
Eli Lilly, Sarepta, Pfizer, Medicare, Novo: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment
Establishment of the TIME subtype According to recent literature, knowledge of the TIME should be the main emphasis…
Synthetic lethality in cancer drug discovery: challenges and opportunities
Hartwell, L. H., Szankasi, P., Roberts, C. J., Murray, A. W. & Friend, S. H. Integrating genetic approaches…
How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…